BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2014

Mar 10, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2014-03-06

Reporting Person: Ajer Jeffrey Robert (SVP, Chief Commercial Of)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-03-06	Common Stock	M	2558	$21.51	Acquired	27938	Direct
2014-03-06	Common Stock	M	14812	$28.23	Acquired	42750	Direct
2014-03-06	Common Stock	S	17370	$78.6316	Disposed	25380	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-03-06	Common Stock	$21.51	M	2558	Disposed	2020-05-11	Common Stock (2558)	Direct
2014-03-06	Common Stock	$28.23	M	14812	Disposed	2021-05-30	Common Stock (14812)	Direct

Footnotes

F1: Transaction made pursuant to a Rule 10b5-1 plan executed on December 12, 2013.

F2: The price in Column 4 is a weighted average price. The prices actually received ranged from $77.48 to $79.59. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: Original option grant vests 6/48th on November 12, 2010 and 1/48th on the 12th of each month thereafter.

F4: Original option grant vests 6/48th on December 1, 2011 and 1/48th on the 1st of each month thereafter.

F5: Reflects the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.